



Contact: Julie Bryant  
VP Business Development and Marketing  
GeneGo, Inc.  
(858) 756 7996  
julie@genego.com

## **BOEHRINGER INGELHEIM EXPANDS GENEGO LICENSES TO GLOBAL AGREEMENT**

**St. Joseph, MI. April 10th, 2007** –GeneGo, Inc., the leading systems biology tools company, announced today that Boehringer Ingelheim have expanded their licensing agreement with GeneGo which now covers Global locations and multiple departments. The agreement covers a suite of software tools and databases for functional data analysis MetaCore, which is used for biomarker discovery, target identification and validation. MetaCore features a unique set of tools for parsing, visualization and analysis of metabolic data and generation of merged metabolic/signaling networks starting from compounds structures. Such capability is key for toxicity studies and medicinal chemistry.

“We have been working for Boehringer Ingelheim for years and we are very pleased with their decision to expand their licenses. This year, we have already seen a substantial increase in the number of MetaCore seats within Pharmaceutical accounts, which is partly due to maturing of functional analysis technology” said Julie Bryant, GeneGo’s VP of Business Development. “We also think that the end users, wet lab scientists, see biologically relevant results using MetaCore that they are not getting from other tools.”

### **About GeneGo, Inc.**

GeneGo, Inc. develops systems biology technology such as compound based [pathway analysis](#), cheminformatics & [bioinformatics software](#) for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, [proteomics](#), metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 4.2™, assists pharmaceutical scientists in the areas of target selection and validation, [data mining](#) in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 2.0™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.

For more information, please visit the company's web site at [www.genego.com](http://www.genego.com)

**MetaCore™, MetaBase™, MetaDrug™, MetaLink™, MetaDiscovery™, MetaTox™ and MetaMiner™, 1-2-3 Workflow™ are trademarks of GeneGo, Inc.**